Authors: Christian H Pfob Sibylle Ziegler Frank Philipp Graner Markus Köhner Sylvia Schachoff Birgit Blechert HansJürgen Wester Klemens Scheidhauer Markus Schwaiger Tobias Maurer Matthias Eiber
Publish Date: 2016/05/20
Volume: 43, Issue: 11, Pages: 1962-1970
Abstract
Positron emission tomography PET agents targeting the prostatespecific membrane antigen PSMA are currently under broad clinical and scientific investigation 68GaPSMA HBEDCC constitutes the first 68Galabelled PSMAinhibitor and has evolved as a promising agent for imaging PSMA expression in vivo The aim of this study was to evaluate the wholebody distribution and radiation dosimetry of this new probeFive patients with a history or high suspicion of prostate cancer were injected intravenously with a mean of 1398 ± 137 MBq of 68GaPSMA HBEDCC range 120–158 MBq Four static skull to midthigh scans using a wholebody fully integrated PET/MRsystem were performed 10 min 60 min 130 min and 175 min after the tracer injection Timedependent changes of the injected activity per organ were determined Mean organabsorbed doses and effective doses ED were calculated using OLINDA/EXMInjection of a standard activity of 150 MBq 68GaPSMA HBEDCC resulted in a median effective dose of 237 mSv Range 108E02 – 246E02 mSv/MBq The urinary bladder wall median absorbed dose 164E01 mGv/MBq range 876E02 – 291E01 mGv/MBq was the critical organ followed by the kidneys median absorbed dose 121E01 mGv/MBq range 716E02 – 175E01 spleen median absorbed dose 413E02 mGv/MBq range 157E02 – 732E02 mGv/MBq and liver median absorbed dose 207E02 mGv/MBq range 180E02 – 257E02 mGv/MBq No drugrelated pharmacological effects occurredThe use of 68GaPSMA HBEDCC results in a relatively low radiation exposure delivering organ doses that are comparable to those of other 68Galabelled PSMAinhibitors used for PETimaging Total effective dose is lower than for other PETagents used for prostate cancer imaging eg 11C and 18FCholineMarkus Schwaiger has received funding from the European Union Seventh Framework Program FP7 under Grant Agreement No 294582 ERC Grant MUMI The development of 68GaPSMA HBEDCC synthesis was supported by SFB 824 DFG Sonderforschungsbereich 824 Project Z1 from the Deutsche Forschungsgemeinschaft Bonn Germany All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards The analysis of patient data was approved by the Ethics Committee of the Technische Universität München permit 5665/13 Informed consent was obtained from all individual participants included in the study
Keywords: